Joshua Daniel Brandstadter, MD, PhD, MSc
Hematology
Headshot of Joshua Daniel Brandstadter, MD, PhD, MSc

Joshua Daniel Brandstadter, MD, PhD, MSc

Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Joshua Daniel Brandstadter, MD, PhD, MSc
Penn Medicine Provider

About me

  • Director, Clinical Research, Center for Cytokine Storm Treatment & Laboratory
  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
  • Instructor A of Medicine (Hematology-Oncology)

Dr. Joshua Brandstadter is a physician-scientist who cares for patients with lymphoma and rare blood disorders, particularly Castleman Disease and histiocytic disorders. In addition to his clinical work, Dr. Brandstadter pursues laboratory-based translational research and serves as Director of Clinical Research for the Center for Cytokine Storm Treatment & Laboratory.

My education and training

  • Duke University Medical CenterMedical School
  • University of Pennsylvania Health SystemResidency
  • University of Pennsylvania Health SystemFellowship

Spoken languages

English
English

Reviews

Average Rating

54 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
He is awesome
Anonymous
October 2026
The provider is an all around professional, knowledgeable, and caring.
Anonymous
September 2026
He explained the new medicine and the side effects. Also any concerns I had were addressed.
Anonymous
September 2026
Dr Brandstadter was very pleasant & though throughout the entire visit. He didn't rush through the visit even though I was late!

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Brandstadter is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

McHugh K, Huang Y, Austin B, Borys L, Irvine AH, Alapat DV, Bagg A, Chadburn A, Lechowicz MJ, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC, Zhang L, Brandstadter JD Idiopathic Multicentric Castleman Disease Unresponsive to One IL-6 Inhibitor May Respond to Another IL-6 Inhibitor , Blood Advances: 2026


Brandstadter JD, Meili S, Zinski J, Cheng HW, Laczko D, Gonzalez MV, George SS, Lim MS, Bagg A, Stanossek Y, Onder L, Lϋtge M, De Martin A, Austin B, Mumau M, Forsyth KS, Pillai V, Ferreira A, Aster JC, Nasta S, Ludewig B, Fajgenbaum DC, Maillard I Vascular smooth muscle cell abundance is a hallmark of Castleman Disease , JCI Insight: 2026


Gonzalez MV, Wang K, Zinski J, Mumau MD, Forsyth KS, Irvine AH, Brandstadter J, Guzman SG, Zhang L, Pierson SK, Austin B, Fajgenbaum DC Clusterin expression and germinal center morphometry help distinguish idiopathic multicentric castleman disease from select lymphadenopathies , Front Immunol, 17: 2026


Austin B, Pierson SK, Dacus KC, Sarmiento Bustamante M, Shyamsundar S, Borys L, McHugh K, Irvine A, Jo Y, Bagg A, Lechowicz M, Alapat D, Chadburn A, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC, Brandstadter JD Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab , Pediatric Blood Cancer: 2026,e70702


Brandstadter JD, Lurain K, Nasta SD, and Fajgenbaum DC Chapter 59: Castleman Disease and Rosai-Dorfman-Destombes Disease , Classical Hematology: 2026,601


Shyamsundar S, Sarmiento Bustamante M, Borys L, Lim MS, Bagg A, Lechowicz MJ, Alapat D, Chadburn A, Srkalovic G, van Rhee F, Austin B, Brandstadter JD, Fajgenbaum DC Breast-implant associated unicentric castleman disease: a case report , Current Problems in Cancer Case Reports, 21: 2026,100404


Laczko D, Pillai V, Frank D, Brandstadter JD, Fajgenbaum DC How I diagnose Castleman disease , American Journal of Clinical Pathology, 165(3): 2026,aqaf147


Kurz L, Lutge M, De Martin A, Cheng H-W, Bugar E, Stanossek Y, Meili S, Brandstadter JD, Maillard I, Onder L, Ludewig B A common progenitor gives rise to fibroblastic reticular cells and vascular smooth muscle cells in murine lymph nodes , Journal of Experimental Medicine, 2(223): 2026,e20242300


McHugh K, Huang Y, Austin B, Borys L, Irvine A, Alapat D, Bagg A, Chadburn A, Lechowicz MJ, Lim M, Srkalovic G, van Rhee F, Fajgenbaum D, Zhang L, Brandstadter J Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor , American Society of Hematology Annual Meeting, Orlando, FL: 2025


Steven Rowe, Mariam Goubran, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Bridget Austin, Kathleen McNicholas, Marley Blommers, Junyan Shi, Lisa K Peterson, Lusia Sepiashvili, Andre Mattman, Joshua D Brandstadter, David C Fajgenbaum, Luke Y C Chen Ferritin, C-Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH , Am J Hematol: 2025


View all publications